Lyra Therapeutics Inc. (LYRA): Price and Financial Metrics


Lyra Therapeutics Inc. (LYRA): $5.54

0.01 (+0.18%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

LYRA Stock Summary

  • LYRA's went public 1.91 years ago, making it older than merely 5.06% of listed US stocks we're tracking.
  • LYRA's price/sales ratio is 186.7; that's higher than the P/S ratio of 98.58% of US stocks.
  • As for revenue growth, note that LYRA's revenue has grown 1,935.71% over the past 12 months; that beats the revenue growth of 99.48% of US companies in our set.
  • Stocks that are quantitatively similar to LYRA, based on their financial statements, market capitalization, and price volatility, are ZSAN, LCTX, ATNM, INFI, and GERN.
  • LYRA's SEC filings can be seen here. And to visit Lyra Therapeutics Inc's official web site, go to www.lyratherapeutics.com.

LYRA Valuation Summary

  • 500 - Internal server error
  • LYRA's price/sales ratio has moved up 0.1 over the prior 16 months.
  • Over the past 16 months, LYRA's EV/EBIT ratio has gone up 12.7.

Below are key valuation metrics over time for LYRA.

Stock Date P/S P/B P/E EV/EBIT
LYRA 2021-08-31 NA 1.6 -2.9 -0.8
LYRA 2021-08-30 NA 1.6 -2.8 -0.7
LYRA 2021-08-27 NA 1.6 -2.9 -0.8
LYRA 2021-08-26 NA 1.6 -2.9 -0.8
LYRA 2021-08-25 NA 1.6 -2.8 -0.7
LYRA 2021-08-24 NA 1.6 -2.9 -0.8

LYRA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • LYRA has a Quality Grade of D, ranking ahead of 21.25% of graded US stocks.
  • LYRA's asset turnover comes in at 0 -- ranking 171st of 186 Medical Equipment stocks.
  • 500 - Internal server error

The table below shows LYRA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0 NA -8.943
2021-03-31 0 NA -6.367
2020-12-31 0 NA -5.992

LYRA Price Target

For more insight on analysts targets of LYRA, see our LYRA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $26.00 Average Broker Recommendation 1 (Strong Buy)

LYRA Stock Price Chart Interactive Chart >

Price chart for LYRA

LYRA Price/Volume Stats

Current price $5.54 52-week high $9.98
Prev. close $5.53 52-week low $3.30
Day low $5.27 Volume 34,800
Day high $5.66 Avg. volume 148,522
50-day MA $5.44 Dividend yield N/A
200-day MA $5.60 Market Cap 72.08M

Lyra Therapeutics Inc. (LYRA) Company Bio


Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. It develops novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat, or ENT, diseases. The firms proprietary XTreo deliver medicines. The company was founded by Carmichael S. Roberts, George M. Whitesides, and Robert S. Langer and is headquartered in Watertown, MA.


LYRA Latest News Stream


Event/Time News Detail
Loading, please wait...

LYRA Latest Social Stream


Loading social stream, please wait...

View Full LYRA Social Stream

Latest LYRA News From Around the Web

Below are the latest news stories about Lyra Therapeutics Inc that investors may wish to consider to help them evaluate LYRA as an investment opportunity.

Lyra Therapeutics Appoints Harlan W. Waksal, MD, as Executive Chairman

Lyra Therapeutics today announced the appointment of Harlan W. Waksal MD, as Executive Chairman. Dr. Waksal most recently served as President, Chief Executive Officer and Member of the Board of Directors of Kadmon Holdings prior to its acquisition by Sanofi in November 2021. With more than 30 years of scientific, clinical development, business development and management experience in the industry, Dr. Waksal holds a successful track record of founding, scaling and advising growth-oriented compan

Yahoo | February 17, 2022

Lyra Therapeutics Kickstarts LYR-210 Pivotal Program in Surgically Naïve Chronic Rhinosinusitis Patients

Lyra Therapeutics Inc (NASDAQ: LYRA) has initiated its Phase 3 ENLIGHTEN I trial of LYR-210 in adult, surgically naïve chronic rhinosinusitis (CRS) patients. LYR-210 is designed to be administered in a brief, non-invasive, in-office procedure and deliver up to six months of continuous anti-inflammatory medication to the sinonasal passages. ENLIGHTEN I will evaluate LYR-210 compared to control in approximately 180 patients who have failed medical management and have not had prior sinus surgery. T

Yahoo | January 24, 2022

Lyra Therapeutics Announces Initiation of LYR-210 Pivotal Phase 3 ENLIGHTEN Program in Surgically Naïve Chronic Rhinosinusitis Patients

Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced the initiation of the Phase 3 ENLIGHTEN I clinical trial of LYR-210 in adult, surgically naïve chronic rhinosinusitis (CRS) patients, with trial sites open for enrollment. LYR-210 is designed to be administered in a brief, non-i

Yahoo | January 24, 2022

Lyra Therapeutics to Present at Upcoming Virtual Investor Conferences

Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced that Maria Palasis, Ph.D., Lyra's President and Chief Executive Officer, will present in a virtual format at three upcoming investor conferences:

Yahoo | November 11, 2021

Lyra Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today reported financial results for the quarter ended September 30, 2021, and highlighted recent accomplishments.

Yahoo | November 9, 2021

Read More 'LYRA' Stories Here

LYRA Price Returns

1-mo -5.78%
3-mo 28.24%
6-mo 31.90%
1-year -30.49%
3-year N/A
5-year N/A
YTD 27.06%
2021 -61.75%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4354 seconds.